Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 141 条
[51]  
Li QD, 2000, ANTICANCER RES, V20, P645
[52]   EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN BLADDER-CANCER AS RELATED TO ESTABLISHED PROGNOSTIC FACTORS, ONCOPROTEIN (C-ERBB-2, P53) EXPRESSION AND LONG-TERM PROGNOSIS [J].
LIPPONEN, P ;
ESKELINEN, M .
BRITISH JOURNAL OF CANCER, 1994, 69 (06) :1120-1125
[53]   A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY [J].
LOEHRER, PJ ;
EINHORN, LH ;
ELSON, PJ ;
CRAWFORD, ED ;
KUEBLER, P ;
TANNOCK, I ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
SAROSDY, MF ;
LOWE, BA ;
BLUMENSTEIN, B ;
TRUMP, D .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1066-1073
[54]   Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species [J].
Matsui, Yoshiyuki ;
Ueda, Shugo ;
Watanabe, Jun ;
Kuwabara, Ichiro ;
Ogawa, Osamu ;
Nishiyama, Hiroyuki .
CANCER RESEARCH, 2007, 67 (03) :1212-1220
[55]   Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer [J].
Matsumoto, H ;
Matsuyama, H ;
Fukunaga, K ;
Yoshihiro, S ;
Wada, T ;
Naito, K .
BRITISH JOURNAL OF CANCER, 2004, 91 (06) :1025-1031
[56]   Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer [J].
Matsumoto, H ;
Wada, T ;
Fukunaga, K ;
Matsuyama, H ;
Naito, K .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (03) :124-130
[57]  
MAULARD C, 1994, CANCER, V73, P394, DOI 10.1002/1097-0142(19940115)73:2<394::AID-CNCR2820730226>3.0.CO
[58]  
2-Y
[59]   Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer [J].
McHugh, LA ;
Griffiths, TRL ;
Kriajevska, M ;
Symonds, RP ;
Mellon, JK .
UROLOGY, 2004, 63 (04) :619-624
[60]   Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens - Evidence of schedule-dependent synergy [J].
McHugh, Lynsey A. ;
Kriajevska, Marina ;
Mellon, John K. ;
Griffiths, Thomas R. .
UROLOGY, 2007, 69 (02) :390-394
12345678910